Michael E. Hurwitz, MD, PhD

Michael Hurwitz, MD, PhD, discusses the ongoing investigation into the use of CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Michael Hurwitz, MD, PhD, discusses the feasibility of utilizing CAR T-cell therapies in patients with solid tumors, such as kidney cancers.

Michael E. Hurwitz, MD, PhD, compares the utility of antiandrogens in nonmetastatic castration-resistant prostate cancer.

Michael E. Hurwitz, MD, PhD, assistant professor of medicine, Yale Cancer, Center, discusses the various patient cohorts in the ongoing phase I/II PIVOT-02 trial.